Tokyo, April 3 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061120) titled 'A Multicenter Prospective Observational Study of Taletrectinib in Patients with Advanced or Recurrent ROS1 Fusion Positive Non Small Cell Lung Cancer (ROSETTA study)(WJOG22925L)' on April 1.
Study Type:
Observational
Primary Sponsor:
Institute - West Japan Oncology Group
Condition:
Condition - Advanced or Recurrent ROS1 Fusion Positive Non Small Cell Lung Cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To evaluate the efficacy and safety of Taletrectinib in ROS1 fusion positive advanced or recurrent non small cell lung cancer (NSCLC)through real-world ...